Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 7/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.44 |
| ▸ | AHCY | P23526 | 2/20 | 0.42 |
| ▸ | HINT1 | P49773 | 2/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316463 | 1.00 | TAS1R3 (0.55) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL14102290 | 0.91 | TAS1R3 (0.66) | TAS1R3TAS1R1IMPDH2IMPDH1AHCY | |
| SCHEMBL14134580 | 0.91 | TAS1R3 (0.54) | TAS1R3TAS1R1IMPDH2IMPDH1HINT1 | |
| SCHEMBL3319089 | 0.89 | TAS1R3 (0.55) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL3319093 | 0.89 | TAS1R3 (0.55) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL3317478 | 0.88 | TAS1R3 (0.45) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL3317477 | 0.88 | TAS1R3 (0.45) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL3316472 | 0.87 | TAS1R3 (0.53) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL24197045 | 0.87 | TAS1R3 (0.44) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL26347601 | 0.87 | TAS1R3 (0.44) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | TAS1R3 4231/4885TAS1R1 3479/4885KDM4E 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.